A neoantigen vaccine against 209 frameshift peptides elicited strong, broad, and long-lasting immunity in people with Lynch syndrome in a phase Ib/II study, offering a novel approach for preventing the range of cancers these individuals are at an elevated risk of developing.
A Wed, study studied this question.